Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trihexyphenidyl Hydrochloride

FDA-approved product (capsule, extended release, oral), marketed as Artane, Tremin, Trihexyphenidyl Hydrochloride.

Registered studies
9
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Trihexyphenidyl Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Tertiary amines
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae9.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

9registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trihexyphenidyl Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trihexyphenidyl Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Benzhexol and Procyclidine for Tremor in Tremor-Predominant Parkinson's Disease

    NCT07810296 · start 2026-09

    Registered record
    Registry ID
    NCT07810296
    Conditions
    Parkinson Disease (PD)
    Interventions
    Benzhexol; Procyclidine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2027-07
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease (PD)
    InterventionBenzhexol; Procyclidine
    PhaseNot applicable
    Registry statusRecruiting

  • Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

    NCT07043803 · start 2025-07-16

    Registered record
    Registry ID
    NCT07043803
    Conditions
    Schizophenia Disorder; Schizoaffective Disorder; Bipolar Disorder; Psychiatric Disorders
    Interventions
    Reduction of anticholinergic medication
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-07-16
    Completion
    2026-05-31
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophenia Disorder; Schizoaffective Disorder; Bipolar Disorder; Psychiatric Disorders
    InterventionReduction of anticholinergic medication
    PhaseNot applicable
    Registry statusCompleted

  • Anticholinergic Deprescription in Schizophrenia

    NCT06562608 · start 2025-02-01

    Registered record
    Registry ID
    NCT06562608
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Anticholinergic Deprescription; No Anticholinergic Deprescription
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-02-01
    Completion
    2029-06-30
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionAnticholinergic Deprescription; No Anticholinergic Deprescription
    PhasePhase 4
    Registry statusRecruiting

  • Accelerating TMS for Cervical Dystonia

    NCT06328114 · start 2024-12-17

    Registered record
    Registry ID
    NCT06328114
    Conditions
    Isolated Cervical Dystonia
    Interventions
    Transcranial Magnetic Stimulation (TMS); Placebo; trihexyphenidyl 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Enrolling by invitation
    Start
    2024-12-17
    Completion
    2029-07-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIsolated Cervical Dystonia
    InterventionTranscranial Magnetic Stimulation (TMS); Placebo; trihexyphenidyl 10mg
    PhasePhase 2
    Registry statusEnrolling by invitation

  • Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

    NCT06554288 · start 2024-10-15

    Registered record
    Registry ID
    NCT06554288
    Conditions
    Pediatric Disorder; Genetic Predisposition; Dystonia, Secondary; Dystonia; Cerebral Palsy, Dystonic-Rigid; Cerebral Palsy, Dyskinetic; Trihexyphenidyl Adverse Reaction; Pharmacogenomic Drug Interaction
    Interventions
    Trihexyphenidyl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-10-15
    Completion
    2029-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Disorder; Genetic Predisposition; Dystonia, Secondary; Dystonia +4 more
    InterventionTrihexyphenidyl
    PhasePhase 1
    Registry statusRecruiting

  • a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics

    NCT03430596 · start 2018-05-01

    Registered record
    Registry ID
    NCT03430596
    Conditions
    Extrapyramidal Syndrome
    Interventions
    Pramipexole; Trihexyphenidyl hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-05-01
    Completion
    2021-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtrapyramidal Syndrome
    InterventionPramipexole; Trihexyphenidyl hydrochloride
    PhaseEarly phase 1
    Registry statusCompleted

  • Neuroimaging of Dystonia

    NCT02046447 · start 2014-05

    Registered record
    Registry ID
    NCT02046447
    Conditions
    Primary Cervical Dystonia; DYT 1 Dystonia
    Interventions
    Primary Cervical Dystonia (Trihexyphenidyl); Controls Primary Cervical Dystonia (Trihexyphenidyl); DYT 1 Dystonia (Healthy Control); DYT 1 Dystonia
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-05
    Completion
    2017-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Cervical Dystonia; DYT 1 Dystonia
    InterventionPrimary Cervical Dystonia (Trihexyphenidyl); Controls Primary Cervical Dystonia (Trihexyphenidyl); DYT 1 Dystonia (Healthy Control); DYT 1 Dystonia
    PhaseNot recorded
    Registry statusCompleted

  • Excessive Crying in Children With Cerebral Palsy and Communication Deficits

    NCT04523935 · start 2005-12-07

    Registered record
    Registry ID
    NCT04523935
    Conditions
    Cerebral Palsy; Excessive Crying; Pain
    Interventions
    Placebo; Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-12-07
    Completion
    2020-08-04
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Palsy; Excessive Crying; Pain
    InterventionPlacebo; Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
    PhasePhase 4
    Registry statusCompleted

  • Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects

    NCT00122044 · start 2003-01

    Registered record
    Registry ID
    NCT00122044
    Conditions
    Dystonia
    Interventions
    trihexyphenidyl
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDystonia
    Interventiontrihexyphenidyl
    PhasePhase 2
    Registry statusCompleted